Karin Amundson

1.1k total citations · 1 hit paper
14 papers, 781 citations indexed

About

Karin Amundson is a scholar working on Molecular Biology, Oncology and Epidemiology. According to data from OpenAlex, Karin Amundson has authored 14 papers receiving a total of 781 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Molecular Biology, 6 papers in Oncology and 3 papers in Epidemiology. Recurrent topics in Karin Amundson's work include Adenosine and Purinergic Signaling (3 papers), Virus-based gene therapy research (3 papers) and Angiogenesis and VEGF in Cancer (3 papers). Karin Amundson is often cited by papers focused on Adenosine and Purinergic Signaling (3 papers), Virus-based gene therapy research (3 papers) and Angiogenesis and VEGF in Cancer (3 papers). Karin Amundson collaborates with scholars based in United States and Austria. Karin Amundson's co-authors include Dana D. Hu‐Lowe, Grant Wickman, Jeffrey H. Chen, Max Hallin, Robert S. Kania, Maren L. Grazzini, David R. Shalinsky, Michele McTigue, Helen Y. Zou and Brion W. Murray and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Karin Amundson

14 papers receiving 751 citations

Hit Papers

Nonclinical Antiangiogenesis and Antitumor Activities of ... 2008 2026 2014 2020 2008 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3
    2008 515 citations Dana D. Hu‐Lowe, Helen Y. Zou et al. Clinical Cancer Research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Karin Amundson United States 6 429 332 260 156 147 14 781
Maher N. Younes United States 19 517 1.2× 498 1.5× 158 0.6× 169 1.1× 83 0.6× 21 1.1k
Ivan Ischenko Germany 19 621 1.4× 507 1.5× 140 0.5× 269 1.7× 105 0.7× 22 1.2k
Urszula M. Polanska United Kingdom 15 489 1.1× 432 1.3× 227 0.9× 209 1.3× 50 0.3× 29 884
Bradley Wubbenhorst United States 14 449 1.0× 281 0.8× 173 0.7× 311 2.0× 198 1.3× 28 1.0k
Vinay Sagar United States 19 712 1.7× 361 1.1× 214 0.8× 231 1.5× 83 0.6× 46 1.3k
François Ringeisen France 14 517 1.2× 373 1.1× 305 1.2× 175 1.1× 112 0.8× 33 899
Jari Sundström Finland 22 484 1.1× 520 1.6× 295 1.1× 332 2.1× 118 0.8× 49 1.2k
Allison Landman United States 9 700 1.6× 449 1.4× 187 0.7× 193 1.2× 63 0.4× 15 955
Dina Leitão Portugal 14 434 1.0× 673 2.0× 193 0.7× 296 1.9× 73 0.5× 28 1.0k
Stephen B. Keysar United States 15 580 1.4× 560 1.7× 270 1.0× 261 1.7× 42 0.3× 31 1.1k

Countries citing papers authored by Karin Amundson

Since Specialization
Citations

This map shows the geographic impact of Karin Amundson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karin Amundson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karin Amundson more than expected).

Fields of papers citing papers by Karin Amundson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Karin Amundson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karin Amundson. The network helps show where Karin Amundson may publish in the future.

Co-authorship network of co-authors of Karin Amundson

This figure shows the co-authorship network connecting the top 25 collaborators of Karin Amundson. A scholar is included among the top collaborators of Karin Amundson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Karin Amundson. Karin Amundson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
Döhrmann, Simon, Qiping Zhao, María Hernández, et al.. (2024). Abstract 2668: CBO421: A novel drug Fc-conjugate to prevent tumor immune evasion via the CD73/adenosine pathway. Cancer Research. 84(6_Supplement). 2668–2668. 1 indexed citations
2.
Döhrmann, Simon, Qiping Zhao, María Hernández, et al.. (2024). Abstract LB131: CBO421, a novel drug Fc-conjugate, inhibits the enzymatic activity of CD73 and triggers CD73 internalization. Cancer Research. 84(7_Supplement). LB131–LB131. 2 indexed citations
3.
Döhrmann, Simon, Jason N. Cole, Karin Amundson, et al.. (2023). 2062. In Vivo Efficacy of CD388, a Novel Drug Fc-Conjugate (DFC), Against Seasonal Subtypes of Influenza in Prophylaxis in Immune Competent Mice, and in a Severe Immunodeficient (SCID) Mouse Model. Open Forum Infectious Diseases. 10(Supplement_2). 1 indexed citations
4.
Döhrmann, Simon, Qiping Zhao, María Hernández, et al.. (2023). 1195 Discovery of CBO421, a first-in-class drug Fc-conjugate (DFC), targeting CD73 in cancer. SHILAP Revista de lepidopterología. A1318–A1318. 1 indexed citations
5.
Döhrmann, Simon, Karin Amundson, Thomas P. Brady, et al.. (2020). 162. CD377, a Novel Antiviral Fc-conjugate, Demonstrates Potent Viral Burden Reduction Against Influenza a (H1N1) in Mouse and Ferret Models. Open Forum Infectious Diseases. 7(Supplement_1). S210–S211. 1 indexed citations
6.
Perez, Omar D., Christopher R. Logg, Kei Hiraoka, et al.. (2012). Design and Selection of Toca 511 for Clinical Use: Modified Retroviral Replicating Vector With Improved Stability and Gene Expression. Molecular Therapy. 20(9). 1689–1698. 112 indexed citations
7.
Ostertag, Derek, Karin Amundson, Ana Paula da Silva, et al.. (2011). Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector. Neuro-Oncology. 14(2). 145–159. 110 indexed citations
8.
Li, Gang, Lianglin Zhang, Enhong Chen, et al.. (2010). Dual Functional Monoclonal Antibody PF-04605412 Targets Integrin α5β1 and Elicits Potent Antibody-Dependent Cellular Cytotoxicity. Cancer Research. 70(24). 10243–10254. 20 indexed citations
9.
Robbins, Joan M., Derek Ostertag, Karin Amundson, et al.. (2010). Intratumoral conversion of flucytosine to 5-fluorouracil using a novel MLV-based replication-competent retroviral vector carrying the cytosine deaminase gene (Toca 511) in an immune-competent model of glioblastoma.. Journal of Clinical Oncology. 28(15_suppl). e13541–e13541. 1 indexed citations
10.
Hu‐Lowe, Dana D., Helen Y. Zou, Maren L. Grazzini, et al.. (2008). Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3. Clinical Cancer Research. 14(22). 7272–7283. 515 indexed citations breakdown →
11.
Marrone, Tami, Dana D. Hu‐Lowe, Maren L. Grazzini, et al.. (2007). PF-00337210, a potent, selective and orally bioavailable small molecule inhibitor of VEGFR-2. Cancer Research. 67. 3992–3992. 7 indexed citations
12.
Hu‐Lowe, Dana D., Maren L. Grazzini, Karin Amundson, et al.. (2006). 71 POSTER Antiangiogenic inhibitor axitinib (AG-013736) renders significant growth inhibition of bevacizumab-refractory xenograft tumors. European Journal of Cancer Supplements. 4(12). 25–25. 1 indexed citations
13.
Yamazaki, Shinji, Maren L. Grazzini, David Romero, et al.. (2005). PK/PD modeling based on mouse xenograft tumor growth inhibition and the correlation to clinical exposure for VEGF/PDGF receptor tyrosine kinase inhibitor AG-013736. Cancer Research. 65. 705–706. 2 indexed citations
14.
Zou, Helen Y., Qiuhua Li, Maren L. Grazzini, et al.. (2004). AG-028262, a novel selective VEGFR tyrosine kinase antagonist that potently inhibits KDR signaling and angiogenesis in vitro and in vivo. Cancer Research. 64. 595–595. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Maher N. Younes Breakdown of academic impact, for papers by Ivan Ischenko Breakdown of academic impact, for papers by Urszula M. Polanska Breakdown of academic impact, for papers by Bradley Wubbenhorst Breakdown of academic impact, for papers by Vinay Sagar Breakdown of academic impact, for papers by François Ringeisen Breakdown of academic impact, for papers by Jari Sundström Breakdown of academic impact, for papers by Allison Landman Breakdown of academic impact, for papers by Dina Leitão Breakdown of academic impact, for papers by Stephen B. Keysar
Rankless by CCL
2026